Dr Reddy's API halt

2026-07-22

Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woes

Dr Reddy's shares fell nearly 7% as brokerages cut forecasts due to weak margins and semaglutide supply disruptions lasting until late October. Analysts indicate recovery depends on supply resumption

reuters · 2026-07-22 20:55 UTC

2026-07-22

India's Dr Reddy's posts quarterly profit slump on semaglutide inventory costs

Dr Reddy's Q1 profit plunged 68.7% to 4.44 billion rupees due to semaglutide inventory costs stemming from an active ingredient impurity. Revenue dropped 5.5% amidst pricing pressures and market compe

reuters · 2026-07-22 03:53 UTC

2026-07-09

India's Dr Reddy's Extends Slide as Semaglutide Setback Threatens First-Mover Edge

Dr Reddy's shares fell after halting semaglutide injections due to an API impurity. Analysts downgraded earnings forecasts, warning the supply disruption could erode the company's market advantage.

reuters · 2026-07-09 20:51 UTC

Media coverage (3)

Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woesreuters
India's Dr Reddy's posts quarterly profit slump on semaglutide inventory costsreuters
India's Dr Reddy's Extends Slide as Semaglutide Setback Threatens First-Mover Edgereuters

Dr Reddy's API halt

Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woes

India's Dr Reddy's posts quarterly profit slump on semaglutide inventory costs

India's Dr Reddy's Extends Slide as Semaglutide Setback Threatens First-Mover Edge

Media coverage (3)

Related topics